Company Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Mendus AB

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 09:21:31 2024-04-18 am EDT			5-day change	1st Jan Change
0.4935 ^SEK	-3.24%		-6.89%	-5.64%

Apr. 16	Mendus AB Announces Board Changes	CI
Mar. 27	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Number of employees: 27

Managers	Title	Age	Since
Alex Karlsson-Parra FOU	Founder	74	01-12-31
Erik Manting CEO	Chief Executive Officer	52	-
Lotta Ferm DFI	Director of Finance/CFO	58	21-02-27
Léopold Bertea CTO	Chief Tech/Sci/R&D Officer	-	22-05-04
Jeroen Rovers CTO	Chief Tech/Sci/R&D Officer	54	-
Sijme Zeilemaker IRC	Investor Relations Contact	37	17-03-01
Anna Koptina Gültekin LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Sven Arne Andréasson BRD	Director/Board Member	71	12-12-31
Helén Tuvesson BRD	Director/Board Member	62	19-12-31
Hans Preusting BRD	Director/Board Member	61	-
Alex Karlsson-Parra FOU	Founder	74	01-12-31
Dharminder S. Chahal BRD	Director/Board Member	48	21-01-21
Andrea van Elsas BRD	Director/Board Member	57	21-01-21
Christine Lind CHM	Chairman	50	19-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	863,148,371	449,913,720 ( 52.12 %)	0	52.12 %

Name	Equities	%	Valuation
Adrianus van Herk 13.72 %	92,715,573	13.72 %	4 M kr
Fjärde AP-fonden 3.146 %	21,253,465	3.146 %	894 558 kr
Holger Blomstrand Byggnads AB 0.4781 %	3,230,350	0.4781 %	135 965 kr
Martin Lindstrom 0.3439 %	2,323,379	0.3439 %	97 791 kr
Erik Manting 0.2135 %	1,442,312	0.2135 %	60 707 kr
Dharminder S. Chahal 0.2126 %	1,436,448	0.2126 %	60 460 kr
FCG Fonder AB 0.1770 %	1,196,085	0.1770 %	50 343 kr
Lennart Sten 0.1406 %	949,980	0.1406 %	39 985 kr
Ivar Nordqvist 0.1334 %	901,401	0.1334 %	37 940 kr
Bengt Anders Andersson 0.1079 %	728,845	0.1079 %	30 677 kr

Mendus AB

Västra Trädgårdsgatan 15

111 53, Stockholm

+46 87 32 84 00

http://mendus.com

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MENDUS AB	-5.64%	46.73M
IQVIA HOLDINGS INC.	-1.78%	41.36B
LONZA GROUP AG	+43.68%	41.3B
MODERNA, INC.	+4.01%	39.61B
CELLTRION, INC.	-15.14%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.38B
MEDPACE HOLDINGS, INC.	+24.76%	11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
UNITED THERAPEUTICS CORPORATION	+7.01%	11.07B

Other Biotechnology & Medical Research